---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-016725"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:49:59.722821+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Q4 ARCALYST rev $122.5M ($417M FY); guides 2025 $560-580M; discontinues mavrilimumab & abiprubart

## Summary
- ARCALYST Q4 net product revenue $122.5M; full year $417.0M (79% YoY growth).
- 2025 ARCALYST revenue guidance $560-580M; expects annual cash flow positive.
- Terminated MedImmune license for mavrilimumab; effective May 22, 2025.
- Discontinued abiprubart Phase 2b trial in Sjögren's Disease; expects $14-17M additional expenses.
- Net loss Q4 $8.9M (vs net income $25.2M); full year net loss $43.2M (vs net income $14.1M).

## SEC filing metadata
- accession: 0001104659-25-016725
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02, 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465925016725/0001104659-25-016725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465925016725/tm257489d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-016725
- JSON: https://secwatch.observer/filing/0001104659-25-016725.json
- Plain text: https://secwatch.observer/filing/0001104659-25-016725.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.